Production, Quality Control and Pharmacokinetic Studies of177Lu-EDTMP for Human Bone Pain Palliation Therapy Trials

Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. possibly, lu-177 ethylenediaminetetramethylene phosphonic acid (177lu-edtmp) is a therapeutic agent which can be widely used in bone palliation therapy. in this study, 177lu-edtmp complex was prepared successfully using synthesized edtmp ligand and 177lucl3. lu-177 chloride was obtained by thermal neutron irradiation (4 × 1013 n.cm-2s-1) of natural lu2o3 samples. radiochemical purity of 177lu-edtmp was determined by itlc (more than 99%). stability studies of the final preparations in the presence of human serum were performed. the biodistribution of 177lu-edtmp and 177lucl3 in wild-type rats was studied by spect imaging. a comparative accumulation study for 177lu-edtmp and 177lucl3 was performed for vital organs up to 7 days. the complex was obtained in high radiochemical purity (more than 99%). the complex was stable in vitro in presence of human serum as well as final formulation. significant bone uptake (> 70%) was observed for the radiopharmaceutical. due to better physical properties of lu-177 compared to sm-153 and acceptable biodistribution results of the compound, 177lu-edtmp seemed to be an interesting new candidate for clinical trials for bone pain palliation therapy